Effects of Semaglutide on heart and kidney health in type 1 diabetes
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)
This study is looking at how the medication Semaglutide might help heart and kidney health for people with type 1 diabetes, especially those who are dealing with weight issues and insulin resistance, to find better treatment options for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10881809 on NIH RePORTER |
What this research studies
This research investigates how the medication Semaglutide, a glucagon-like peptide-1 receptor agonist, affects cardiovascular and kidney health in individuals with type 1 diabetes. It aims to understand the relationship between obesity, insulin resistance, and heart and kidney complications in this population. By analyzing various health metrics, including cardiac function and arterial stiffness, the study seeks to provide insights into potential new treatments that could improve outcomes for patients with type 1 diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with type 1 diabetes.
Not a fit: Patients with type 1 diabetes who are under 21 years old or those with contraindications to Semaglutide may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cardiovascular and kidney health for patients with type 1 diabetes.
How similar studies have performed: Previous studies have shown that glucagon-like peptide-1 receptor agonists can improve cardiovascular outcomes in type 2 diabetes, suggesting potential for success in similar applications for type 1 diabetes.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Nadeau, Kristen Jane — University of Colorado Denver
- Study coordinator: Nadeau, Kristen Jane
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.